naion glp-1 Risk of nonarteritic anterior ischemic optic neuropathy (NAION) in patients prescribed semaglutide - Novo Nordisk The question everyone is asking.

Description

Eur J Ophthalmol

Once you reach your goal, you can: Taper off the medication Move to a lower maintenance dose Stay on temporarily with continued support We help clients transition off GLP-1s while keeping their progress

If semaglutide at a dosage of 0.4 mg/day leads to resolution of steatohepatitis in 59% of cases, no significant difference emerged in the improvement of fibrosis compared to placebo

Some experts caution that a clear causal link has not yet been established between the medication and these mental health issues, but in my view whether its causation or correlation doesnt really matter

Many are trying to address this by expanding their range of protein-rich products and creating GLP-1 companion products, but it probably wont be enough